Company Overview and News

 
DirectMoney a leading ASX gainer after revealing Alceon investment

2018-02-13 proactiveinvestors.com.au
DirectMoney Ltd (ASX:DM1) is an ASX leading gainer intra-day on news of a strategic investment by alternative investment manager Alceon.

 
DirectMoney Ltd pending update on capital raising

2016-06-29 proactiveinvestors.com.au
DirectMoney Limited (ASX:DM1) has been granted a trading halt by the ASX, pending the release of a proposed capital raising. The halt will remain in place until the opening of trade on Friday 1st July 2016, or earlier if an announcement is made to the market. DirectMoney operates in the Australian marketplace lending industry and aims to connect borrowers and investors. The company has recently been reaching agreements with institutions regarding loan sale facilities.

 
DirectMoney Ltd posts record lending quarter as fin-tech spreads wings

2016-05-02 proactiveinvestors.com.au
Australian fin-tech DirectMoney (ASX:DM1), has posted a record 48% growth in new loans during the quarter ended 31 March 2016, relative to the previous quarter. The only ASX listed fin-tech lender brings together borrowers and lenders through a web-based platform to offer unsecured loans. During the quarter ended 31 March 2016, $4.71 million of loans to 219 borrowers were issued, including $1.92 million in March 2016, which was a record month.

 
THIRD QUARTER FY 2016 UPDATE

2016-05-02 asx.com.au

 
 
 
 
Appendix 3B

2016-04-01 asx.com.au

 
Investor Update

2016-03-21 asx.com.au

 
Directmoney Ltd sign up with Comprehensive Credit Reporting community

2016-03-17 proactiveinvestors.com.au
Marketplace lending company Directmoney Ltd has signed an agreement with credit reporting bureau, Dun & Bradstreet, bringing Directmoney into the Australian Comprehensive Credit Reporting (CCR) community

 
Directmoney Ltd signs key agreement with Dun & Bradstreet

2016-03-17 proactiveinvestors.com.au
Marketplace lending company Directmoney Ltd has signed an agreement with credit reporting bureau, Dun & Bradstreet, bringing Directmoney into the Australian Comprehensive Credit Reporting (CCR) community

 
Release of Shares from Escrow

2016-03-14 asx.com.au

 
Appendix 3B

2016-02-25 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...